Search results for "Vitrectomy"

showing 10 items of 58 documents

Vitrectomía enzimática por inyección intravítrea de plasmina autóloga como tratamiento inicial de las membranas epirretinianas maculares y el síndrom…

2009

espanolObjetivo: Determinar si la inyeccion intravitrea de plasmina es efectiva en el tratamiento de las membranas epirretinianas maculares (MEM) y el sindrome de traccion vitreomacular (STVM), sin necesidad de asociar vitrectomia quirurgica. Material y metodo Diseno: Estudio piloto prospectivo, de intervencion, serie de casos. Pacientes: Siete pacientes, cuatro con membrana epirretiniana macular y tres con sindrome de traccion vitreomacular. Tratamiento: Inyeccion intravitrea de 0,2 ml de plasmina autologa bajo anestesia topica. La plasmina fue obtenida por un metodo simplificado modificado por adiccion de uroquinasa. Principales medidas: Grado de separacion de la membrana epirretiniana de…

Pars planamedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatmentVitrectomyAgudeza visualTopical anesthesiaOphthalmologyMedicinevitreolisis enzimáticabusiness.industryRetinal tractionOutcome measuressíndrome de tracción vitreomacularmembrana epirretinianaSindrome devitrectomía enzimáticaeye diseasesSurgeryvitreolisis farmacológicaOphthalmologymedicine.anatomical_structurePlasmina autólogasense organsmedicine.symptombusinessArchivos de la Sociedad Española de Oftalmología
researchProduct

Vascular changes after vitrectomy for rhegmatogenous retinal detachment: optical coherence tomography angiography study

2020

Purpose: To analyse the postoperative foveal avascular zone (FAZ) area, superficial vessel density (SVD) and deep vessel density (DVD) and their correlation with functional (best-corrected visual acuity, BCVA) and anatomical outcomes (foveal macular thickness, FMT) after surgery for rhegmatogenous retinal detachment (RRD) repair. Method: Patients with RRD eyes, successfully treated with a single pars plana vitrectomy (PPV) with gas tamponade and a minimum 12 months follow-up, were re-examined. Foveal avascular zone (FAZ) area, SVD, DVD and FMT were evaluated by using optical coherence tomography angiography (OCTA) and compared to fellow eye. Results: Fifty-six patients with macula-on and 37…

Pars planamedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatmentvitrectomyVitrectomyfoveal avascular zone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFovealOphthalmologyMedicinebusiness.industryrhegmatogenous retinal detachmentRetinal detachmentRetinalGeneral MedicineOptical coherence tomography angiographymedicine.diseaseeye diseasesOphthalmologymedicine.anatomical_structuresuperficial and deep vessel densitychemistry030221 ophthalmology & optometryfoveal avascular zone; rhegmatogenous retinal detachment; superficial and deep vessel density; vitrectomysense organsTamponademedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Retinopathy of prematurity-current diagnosis and management

1993

Despite advances in ophthalmological care of premature infants, retinopathy of prematurity (ROP) remains a still unsolved problem for paediatricians as well as ophthalmologists. A survey of the current literature concerning drug therapy and surgical management as related to the different stages of ROP is given. The classification system for ROP according to the International Committee is presented as well as our screening policy in relation to the literature. The effectiveness in preventing severe cases of ROP and the toxicity of vitamin E supplementation in high-risk premature infants is still disputed and no recommendations can be given. Cryotherapy is recommended in symmetric cases of st…

Pediatricsmedicine.medical_specialtygenetic structuresmedicine.medical_treatmentEye diseaseVitrectomyCryotherapyCryosurgeryPharmacotherapyVitrectomymedicineHumansMass ScreeningRetinopathy of Prematuritybusiness.industryInfant NewbornRetinal detachmentRetinopathy of prematurityPrognosismedicine.diseaseeye diseasesSurgeryScleral BucklingPediatrics Perinatology and Child Healthsense organsbusinessScleral bucklingInfant PrematureRetinopathyEuropean Journal of Pediatrics
researchProduct

Entfernung von subfovealem Perfluorcarbon durch ein therapeutisches Makulaforamen

2018

Suction (medicine)medicine.medical_specialtybusiness.industrymedicine.medical_treatmentFovea centralisRetinal detachmentVitrectomymedicine.disease03 medical and health sciencesOphthalmology0302 clinical medicinemedicine.anatomical_structureOphthalmology030221 ophthalmology & optometrymedicinebusiness030217 neurology & neurosurgeryKlinische Monatsblätter für Augenheilkunde
researchProduct

Desprendimiento del vítreo posterior y vitreolisis farmacológica: la nueva era de la vitrectomía enzimática

2007

Vitreous DetachmentOphthalmologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentOphthalmologymedicineVitrectomybusinessFibrinolysinmedicine.drug
researchProduct

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

2019

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an importan…

intravitrealgenetic structuresBevacizumabmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceVitrectomyReviewvascular endothelial growth factor/antagonists &ampbevacizumabPharmacologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsRanibizumabinhibitorsVascular endothelial growth factor/antagonists & inhibitorsMedicineDistribution (pharmacology)Pharmacokineticsranibizumab030304 developmental biologyAflibercept0303 health sciencesbusiness.industryafliberceptvascular endothelial growth factor/antagonists & inhibitorsIntravitreal administrationMacular degenerationmedicine.diseaseBevacizumabAge-Related Macular Degeneration030221 ophthalmology & optometryRanibizumabbusinessAfliberceptIntravitrealpharmacokineticsmedicine.drug
researchProduct

Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a s…

2020

Purpose: to conduct a systematic review with network meta‐analysis (NMA) of randomized clinical trials (RCTs) comparing panretinal photocoagulation (PRP) versus anti‐vascular endothelial growth factor (VEGF) treatment alone or in combination with PRP, for proliferative diabetic retinopathy (PDR).Methods: PubMed, Medline and Embase databases were searched for RCTs comparing PRP versus intravitreal anti‐VEGF therapy and/or combined PRP and intravitreal anti‐VEGF for PDR. The primary outcome measures were the mean best corrected visual acuity (BCVA) change and the regression of neovascularization. Mean change of central macular thickness (CMT), the subgroup analyses of patients without diabeti…

medicine.medical_specialtyBevacizumabgenetic structurespegaptanibmedicine.medical_treatmentPegaptanibNetwork Meta-AnalysisVisual AcuityVitrectomyAngiogenesis Inhibitorsbevacizumablaw.inventionNeovascularization03 medical and health sciences0302 clinical medicineRandomized controlled trialaflibercept; bevacizumab; intravitreal anti-VEGF; panretinal photocoagulation; pegaptanib; proliferative diabetic retinopathy; ranibizumabintravitreal anti-VEGFlawOphthalmologyVitrectomymedicineHumansranibizumabAfliberceptDiabetic RetinopathyLaser Coagulationbusiness.industryafliberceptGeneral MedicineDiabetic retinopathymedicine.diseasepanretinal photocoagulationeye diseasesOphthalmologyIntravitreal Injections030221 ophthalmology & optometrysense organsRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugproliferative diabetic retinopathy
researchProduct

Radiäre Optikusneurotomie (RON) bei retinalen Zentralvenenverschlüssen

2007

Background Compression in the lamina cribrosa is discussed as a reason for central retinal vein occlusion. Radial optic neurotomy should release the pressure and increase venous blood outflow. Patients and methods In a clinical trial 27 eyes with central retinal vein occlusion (22 eyes with clinical ischaemia, 5 eyes with continuous disc oedema and visual acuity below 4/10) underwent surgical decompression by vitrectomy and radial optic neurotomy. During surgery the intravenous pressure in the central vein was tested by infusion dynamometry before and right next to the incision. Follow up-time minimally was 1.5 years. Results Infusion dynamometry demonstrated a decrease of the central vein …

medicine.medical_specialtyCentral retinal veinVisual acuityRetinal Veingenetic structuresbusiness.industrymedicine.medical_treatmentVitrectomymedicine.diseaseNeurotomyeye diseasesSurgeryOphthalmologymedicine.anatomical_structureCentral retinal vein occlusionOcclusionmedicinesense organsmedicine.symptomVeinbusinessKlinische Monatsblätter für Augenheilkunde
researchProduct

Morbus Eales – 10 Jahre Erfahrung mit einem seltenen Krankheitsbild

2009

BACKGROUND: Eales’ disease is an uncommon vasoproliferative retinal disease affecting otherwise healthy young men. We report on our treatment results in a large patients group with long-term follow-up. PATIENTS AND METHODS: The treatment results in 50 eyes (35 patients) with Eales’ disease, that were cosecutively treated from May 1995 to August 2005, were analysed retrospectively. Recorded data included age, sex, race, association of systemic disease, medications, laboratory evaluation and the surgical treatment. Mean follow-up was 5.8 years (minimum: 3.2, maximum: 8.6 years). RESULTS: Systemic and laboratory evaluations detected a factor V Leiden mutation (4 × ), vestibuloauditory problems…

medicine.medical_specialtySystemic diseaseVisual acuitygenetic structuresbusiness.industrymedicine.medical_treatmentVitrectomyRetinalmedicine.diseaseeye diseasesSurgeryOphthalmologychemistry.chemical_compoundchemistryEales diseasemedicineCoagulopathyFactor V Leidenmedicine.symptomVasculitisbusinessKlinische Monatsblätter für Augenheilkunde
researchProduct

Nd:YAG-Laserung einer retrohyaloidalen Blutung nach Venenastverschluss

2006

Background A retrohyaloidal haemorrhage can be caused by different underlying diseases. Usually dense haemorrhages are treated by early vitrectomy. We want to report the successful treatment of a retrohyaloidal haemorrhage by means of Nd:YAG laser membranotomy. Materials and methods A 47-year-old man noticed two weeks before presentation a sudden visual loss in the left eye. Visual acuity on the first visit was c. c. 20/32 OD and c. c. 20/400 ex. OS. Dilated fundus examination of the left eye showed multiple intraretinal haemorrhages in the superior periphery and a dense retrohyaloidal haemorrhage over the macula. Anamnestic risk factors for ocular bleeding were systemic hypertension in con…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industrymedicine.medical_treatmentVitrectomyAnterior surfaceSudden visual lossDilated fundus examinationmedicine.diseaseeye diseasesSurgeryOphthalmologyNd:YAG lasermedicinesense organsEpiretinal membranemedicine.symptomRetinal branch vein occlusionbusinessKlinische Monatsblätter für Augenheilkunde
researchProduct